Authors: Mohammad Tinawi.
Background: This timely update in nephrology is based on the proceedings of The American Society of Nephrology (ASN) Kidney Week that was held in San Diego, California between October 23, and October 27, 2024. The meeting had 4 sessions dedicated to high-impact clinical trials and late-breaking science.
Methods: This update will present 12 studies including 10 clinical trials. Each trial was published in a major peerreviewed journal on the day of the presentation. This will provide the reader with the opportunity to refer to the published study in its entirety. IgA nephropathy (IgAN) management was a major theme in the meeting, and 5 clinical Trials on that topic are included. Other topics included in this review cover kidney transplantation, sodium-glucose cotransporter 2 (SGLT2) inhibitors in chronic kidney disease (CKD), acute kidney injury (AKI), the role of APOL1 risk variants, semaglutide in non-diabetic CKD patients, potassium binders in hemodialysis patients, and blood pressure management strategies in non-cardiac surgery patients.
Results: For each study a brief background will be provided, followed by the results of each individual study, then a conclusion and a statement about the study limitations. Conclusions: This update is a window into recent progress in renal medicine. Advances in basic science are propelling novel medications in the field of nephrology with the potential of impacting direct patient care. The excitement in the renal community is palpable
View/Download pdf